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SUMMARY
Introduction In liver diseases, all components of the haemostatic system are changed and the degree 
of dysfunction is proportional to hepatocellular damage. During the liver transplantation, values of hae-
mostatic parameters show substantial changes, while postoperatively there is a gradual normalisation 
of the haemostatic system function.
Objective The aim was to monitor the changes of the haemostatic system intraoperatively and postop-
eratively, including the dynamics at which physiological values of parameters are reached after trans-
plantation.
Methods There were 17 cadaveric transplantations performed at the Clinical Centre of Vojvodina in 
the period from June 2008 to February 2012. The following parameters were tested: platelets, activated 
partial thromboplastin, prothrombin and thrombin time, fibrinogen, euglobulin clot lysis time, D-dimer, 
antithrombin and heparinemia. The results were presented intraoperatively in phases of transplantation, 
and postoperatively from day 1 to day 7, ending with postoperative day 14.
Results During transplantation, the most pronounced disorders among those observed are: thrombocyto-
penia (96±66.1×109/L), prolonged activated partial thromboplastin (1.80±0.8 R), prothrombin (1.59±0.4 R) 
and thrombin time (2.03±1.7 R), hypofibrinogenemia (2.13±0.5 g/L), hyperfibrinolysis (29±12.0 min), 
increase of D-dimer (1393±1220.4 ng/mL) and decrease of antithrombin (61±18.0%). Further monitoring 
after transplantation from postoperative day 1 revealed a gradual normalisation in the values, reaching 
physiological values for all parameters on postoperative day 14, except for the sustained high value of 
D-dimer (2606±1055.1 ng/mL). Heparinemia was within the prophylactic range (0.26±0 IU/mL).
Conclusion Thorough monitoring of the haemostatic system parameters in liver transplantations is of 
great importance, as it enables the use of optimal substitution therapy during and after transplanta-
tion, as well as an adequate postoperative thromboprophylaxis. Our study has shown normalisation of 
investigated laboratory parameters within 7-14 days after transplantation.
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INTRODUCTION
In liver diseases, all components of the hae-
mostatic system are changed as a result of de-
creased synthesis of the most of coagulation 
factors and impaired clearance. These changes 
correlate to the level of hepatocellular damage. 
The disorder of the liver’s synthetic function 
is manifested by decreased levels of coagula-
tion factors (F), which is one of the first in-
dicators of liver disease. The drop of the FVII 
coagulation level primarily appears due to its 
short half-life [1, 2], while hypofibrinogenemia, 
decrease of FV level [3] and levels of other co-
agulation factors are indicators of a poor prog-
nostic outcome since their level is decreased 
only in cases of severe liver damage, indicating 
the terminal stadium of the disease. In addi-
tion to decrease in synthesis, the structure of 
synthesized coagulation factors and inhibitors 
is altered. Moreover, there is a decrease in syn-
thesis and an increase in catabolism of plas-
minogen and plasmin inhibitors. Impaired 
clearance of the activated coagulation factors 
and plasminogen activators contributes to fur-
ther deterioration of haemostasis. Decreased 
number of platelets, which is a consequence of 
hypersplenism, is frequently accompanied by 
the impaired platelet function.
Liver diseases are characterised by derange-
ment of physiological balance within the hae-
mostatic system [3]. Some changes result in 
deterioration of its functions, increasing the 
risk of haemorrhagic complications, while, 
on the other hand, there are such changes that 
result in the increased activity of the haemo-
static system, followed by the increased risk of 
thromboembolic complications. Haemostatic 
disorders in the chronic liver diseases which 
can result in bleeding include: thrombocytope-
nia, platelet dysfunction, reduced levels of most 
coagulation factors, hypofibrinogenemia and 
low levels of α2-antiplasmin [4]. These changes 
are balanced by pro-haemostatic alterations 
like: reduced synthesis of natural coagulation 
inhibitors, decreased levels of plasminogen and 
increased levels of FVIII [5] and it might easily 
result either bleeding diathesis or thrombotic      
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events [6]. In patients with the cirrhosis and esophageal 
varices, the incidence of variceal bleeding ranges from 19-
40% [7]. Portal vein thrombosis is a common complication 
with the prevalence of 10-25% [8, 9, 10]. Approximately 
0.8% of all hospitalized patients with cirrhosis have had a 
non-portal venous thromboembolism, deep vein throm-
bosis and pulmonary embolism [11].
During the liver transplantation, most of the patients 
manifest multifactorial disorders in their haemostatic bal-
ance [12]. By convention, the surgical procedure is divided 
into the following phases of surgery: preanhepatic, anhe-
patic, reperfusion and postoperative phase. Preanhepatic 
phase is characterised by the hyperfibrinolysis and base-
line hypocoagulable state which deteriorates mildly in the 
presence of surgical stress [6]. In anhepatic phase, there is 
a loss of coagulation factor synthesis and clearance, with 
dramatic changes in the activated partial thromboplastin 
time and prothrombin time [13]. The increased levels of 
tissue plasminogen activator (t-PA) secondary to release 
from the endothelial cells and decreased clearance in 
absence of liver can lead to hyperfibrinolysis with con-
sequent afibrinogenaemia [14] and severe bleeding [15]. 
Profound coagulation abnormalities are related primarily 
to thrombocytopenia because of entrapment of platelets 
in the liver graft and the heparin-like effect of the donor 
liver dominated in the reperfusion phase [6] due to the 
release of heparin-like substances from the grafted liver. 
Increased clearance of t-PA and increased production of 
plasminogen activator inhibitors (PAI-1) lead to gradual 
dissolution of the hyperfibrinolysis [6]. Postoperative 
phase is characterised by thrombocytopenia and hyper-
coagulability [6].
Laboratory findings that are most frequently used in 
monitoring of haemostatic system in liver diseases are 
platelet count, prothrombin time, levels of individual co-
agulation factors and inhibitors, and euglobulin clot lysis 
time, where their values are successively worsening with 
the progression of disease.
OBJECTIVE
The objective of this study was to monitor the changes 
of haemostatic system activity intraoperatively, as well 
as postoperatively, and to estimate the time required for 
achieving physiological values of haemostatic parameters 
after orthotopic liver transplantation.
METHODS
The follow up was conducted on a cohort of 17 patients, 6 
women and 11 men, who were subjected to cadaveric liver 
transplantation at the Clinical Centre of Vojvodina (KCV) in 
the period from June 2008 to February 2012. In the majority 
of cases, the aetiology of liver insufficiency was liver cirrho-
sis caused by viral hepatitis B and C, which was diagnosed in 
12 patients in total. Demographic and clinical characteristics 
of the study population are presented in Table 1.
Laboratory testing was carried out at the laboratory of the 
Department of Thrombosis, Haemostasis and Haematology 
Diagnostics of the KCV Centre of Laboratory Medicine and 
the KCV Emergency Laboratory. Pre-, intra- and postopera-
tive dosing of the substitution therapy and antifibrinolytics 
was based on the laboratory findings as well as clinical find-
ings and it was given in order to achieve the optimal state of 
coagulation. Platelet concentrate was administered in case 
of severe thrombocytopenia, and fresh frozen plasma and 
cryoprecipitate for significant deficiency of coagulation fac-
tors. In order to achieve an optimal level of antithrombin, 
concentrate of antithrombin was given before, during and 
after the transplantations. Antifibrinolytic therapy with 
tranexamic acid was given during the transplantations in 
a small dose before reperfusion, then depending on the 
laboratory findings dose was adjusted in the reperfusion 
phase, or in preanhepatic phase if the patient had hypo-
coagulability. The following haemostatic parameters were 
tested: platelet count (PLT), activated partial thromboplas-
tin time (aPTT), prothrombin time (PT), thrombin time 
(TT), fibrinogen (FBG), euglobulin clot lysis time (ECLT), 
D-dimer, antithrombin (AT) and heparinemia (anti-Xa), 
and the tests were performed immediately after sampling 
blood for analysis. The test samples were taken intraopera-
tively in all phases of transplantation according to the fol-
lowing schedule: prior to preanhepatic phase, 30 minutes 
after clamping blood vessels in anhepatic phase, after graft 
reperfusion in postanhepatic phase and at the end of the 
operation, and postoperatively on a daily basis for 14 days, 
obtained by venepuncture of cubital vein, using the tubes 
containing anticoagulant K2 EDTA for determining platelet 
count from blood sample, and 3.2% sodium citrate for hae-
mostatic testing. Citrated plasma was separated after spin-
ning at 2700 G for 6 minutes. Platelet count was determined 
by means of the automated haematology analysers Beckman 
Coulter HmX (Mervue, Galway, Ireland Inc.) at the Emer-
gency Laboratory during transplantation, and on Cell Dyn 
Sapphire (Abbott Diagnostic, USA) from postoperative day 
1. The haemostatic tests were performed on ACL units – 
automated coagulometers, manufactured by IL (Instrumen-
tation Laboratory, Milano, Italy). Coagulometer ACL 9000 
was used to determine aPTT, PT, TT, FBG, with reagents: 
HemosIL APTT-SP Liquid, RecombiPlasTin 2G, Thrombin 
Table 1. Demographic and clinical characteristics of patients (N=17)
Characteristics Value
Age (years)
Mean 51.6±7.3
Range 38–61
Gender
Female 6
Male 11
Diagnosis
Hepatitis B 7
Hepatitis C 5
Hepatocellular carcinoma 4
Autoimmune 3
Follow-up (years)
Mean 8.6±7.7
Range 1–27
Variceal bleeding 2
Thromboembolic events 1
The values are expressed as mean ± SD (range), and number of patients.  
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Time IL, HemosIL Fibrinogen-C XL according to Clauss 
method. Determination of ECLT was performed manually, 
with incubation in water bath at 37°C. Coagulometer ACL 
7000 was used for determining D-dimer and the level of AT 
activity, with the reagents: HemosIL D-Dimer and HemosIL 
Antithrombin. Heparin level in plasma was measured with 
coagulometer ACL 200, with HemosIL Heparin reagents. All 
reagents were produced by IL (Instrumentation Laboratory, 
Milano, Italy).
The results were statistically processed by descriptive 
statistical method, and the descriptive statistical data were 
presented in tables and illustrated by graphs, as the highest, 
mean and lowest values of the tested haemostatic param-
eters, and standard deviation thereof as a variability meas-
ure, starting from the intraoperative findings in phases of 
transplantation, followed by postoperative daily checks 
from day 1 to day 7, ending with the liver transplantation 
postoperative day 14.
RESULTS
During the liver transplantation, the laboratory values of 
haemostatic parameters showed substantial changes, while 
postoperatively there was a gradual normalisation in the 
function of the haemostatic system which was apparent as 
early as the first week, reaching physiological values for all 
tested parameters on postoperative day 14, except for the 
sustained high value of D-dimer (Table 2).
The majority of patients had mild thrombocytopenia 
(116±89.2×109/L) at the beginning of transplantation. 
During transplantation, PLT count was decreased, more 
pronouncedly in the anhepatic phase (96±66.1×109/L), 
while from postoperative day 6 there was a gradual in-
crease in PLT count values, reaching the normal PLT val-
ues (147±107.3×109/L) on postoperative day 14 (Table 2 
and Graph 1).
Table 2. Intraoperative and postoperative levels of haemostatic parameters (mean±SD and range)
Phases and 
days of liver 
transplantation
Haemostatic parameters with normal values
PLT 
(×109/L) aPTT (R) PT (R) TT (R) FBG (g/L) ECTL (min.) D-dimer  
(ng/mL) AT (%) aXa (IU/mL)
140–400 0.83–1.30 0.93–1.30 0.85–1.30 2.20–4.96 >120 <230 75–122 0.10–0.40
PAH
Mean±SD 116±89.2 1.19±0.2 1.42±0.3 1.87±1.6 2.28±0.9 59±42.3 1229±1206.6 61±18.0
/
Range 29–372 0.98–1.70 1.10–2.13 1.15–7.70 1.13–3.83 6–120 292–4950 39–111
AH
Mean±SD 96±66.1 1.43±0.5 1.38±0.3 2.03±1.7 2.41±0.8 29±12.0 1110±1383.1 71±16.0
/
Range 25–262 0.87–2.85 1.12–2.20 1.15–7.70 1.19–4.17 5–50 346–6250 35–105
PR
Mean±SD 100±54.1 1.80±0.8 1.59±0.4 2.01±1.5 2.13±0.5 55±31.1 1393±1220.4 72±16.7
/
Range 32–213 1.28–4.27 1.26–3.11 1.02–7.70 1.28–2.89 20–120 399–5490 45–117
POP
Mean±SD 91±58.0 1.41±0.3 1.52±0.2 2.16±1.7 2.64±0.6 >120 1194±1184.7 82±10.0
/
Range 33–206 1.10–2.13 1.31–2.03 1.00–7.70 1.93–3.71 335–5077 62–92
1
Mean±SD 75±54.3 1.25±0.2 1.48±0.2 1.28±0.2 3.46±0.7 >120 1027±795.8 80±10.0 0.20±0.2
Range 15–199 0.96–1.69 1.14–1.95 1.05–1.76 1.96–4.54 258–2733 61–99 0.01–0.46
2
Mean±SD 74±54.4 1.15±0.4 1.36±0.2 1.64±1.6 3.44±0.7 >120 1049±696.8 87±10.5 0.32±0.3
Range 16–215 0.80–2.67 1.07–1.74 1.02–7.70 2.11–4.81 352–2768 73–108 0.17–0.83
3
Mean±SD 70±53.1 1.05±0.2 1.33±0.3 1.24±0.1 3.30±0.7 >120 1184±1053.3 88±11.1 0.23±0.1
Range 13–199 0.77–1.83 0.92–1.64 1.06–1.49 2.10–4.97 344–3935 63–107 0.10–0.33
4
Mean±SD 72±60.3 0.96±0.1 1.31±0.2 1.24±0.1 3.10±0.8 >120 1676±1157.5 88±10.6 0.25±0.1
Range 13–242 0.74–1.08 0.96–1.60 1.01–1.48 1.75–5.04 454–4393 73–110 0.13–0.44
5
Mean±SD 66±55.6 0.93±0.1 1.31±0.2 1.19±0.1 3.20±0.5 >120 2156±1354.4 84±8.2 0.25±0.1
Range 17–190 0.73–1.21 0.98–1.54 1.00–1.45 2.36–4.17 765–4655 74–99 0.16–0.39
6
Mean±SD 77±67.4 0.96±0.1 1.33±0.4 1.19±0.1 3.34±0.8 >120 2246±1313.9 82±7.9 0.25±0.1
Range 11–240 0.74–1.34 1.03–2.55 1.02–1.39 2.29–4.85 695–4753 72–98 0.20–0.33
7
Mean±SD 94±74.1 0.94±0.1 1.27±0.3 1.17±0.1 3.45±0.9 >120 2089±991.7 83±10.2 0.24±0.2
Range 4–252 0.73–1.22 1.01–2.13 0.93–1.43 2.25–5.23 866–4267 60–100 0.07–0.51
14
Mean±SD 147±107.3 0.98±0.1 1.17±0.2 1.19±0.2 3.66±1.3 >120 2606±1055.1 85±16.3 0.35±0.2
Range 15–390 0.81–1.21 0.86–1.56 0.88–1.59 1.64–5.63 953–4740 62–122 0.14–0.64
PAH – preanhepatic phase; AH – anhepatic phase; RP – reperfusion phase; POP – postoperative; SD – standard deviation; PLT – platelet; aPTT – activated partial 
thromboplastin time; R – ratio of sample clotting time and clotting time of normal control plasma; PT – prothrombin time; TT – thrombin time; FBG – fibrinogen; 
ECLT – euglobulin clot lysis time; AT – antithrombin; aXa – anti-factor Xa activity
Graph 1. Changes in platelet count (PLT) during and after the liver 
transplantation
PAH – preanhepatic phase; AH – anhepatic phase; RP – reperfusion phase; POP 
– postoperative; 1–7, 14 – days     
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Graph 2. Changes in activated partial thromboplastin time (aPTT) 
during and after the liver transplantation
Graph 3. Changes in prothrombin time (PT) during and after the liver 
transplantation
Graph 6. Changes in euglobulin clot lysis time (ECLT) during the liver 
transplantation
Graph 4. Changes in thrombin time (TT) during and after the liver 
transplantation
Graph 5. Changes in fibrinogen (FBG) during and after liver trans-
plantation
Graph 7. Changes in D-dimer during and after the liver transplantation
Graph 9. Changes in anti-Factor Xa activity (aXa) after the liver trans-
plantation
Graph 8. Changes in antithrombin (AT) during and after the liver 
transplantation  
612
  
doi: 10.2298/SARH1310608N
Prolonged aPTT in anhepatic phase of transplantation 
resulted from the loss of coagulation factor synthesis in the 
absence of liver (1.43±0.5 R), while in reperfusion phase it 
was due to transplant’s heparin release (1.80±0.8 R). Post-
operatively, aPTT was normalised from postoperative day 
1 (1.25±0.2 R) (Table 2 and Graph 2).
Slightly prolonged PT (1.42±0.3 R) was evident in the 
majority of patients in preanhepatic phase, which was 
more pronounced during transplantation in reperfusion 
phase (1.59±0.4 R). PT normalised (1.27±0.3 R) on post-
operative day 7, which was consistent with the gradual 
normalisation of the coagulation factor levels (Table 2 and 
Graph 3).
Prolonged TT during transplantation in preanhepatic 
phase (1.87±1.6 R), anhepatic (2.03±1.7 R) and reperfusion 
phases (2.01±1.5 R) occurred due to hyperfibrinolysis, and 
as a result of heparin release from the grafted liver in reper-
fusion phase. First 2 days after transplantation, slightly 
prolonged TT was a laboratory effect of the intravenous 
unfractionated heparin. Normal TT value (1.24±0.1 R) was 
recorded on postoperative day 3 (Table 2 and Graph 4).
Intraoperatively, there was an observed drop in the FBG 
level (2.13±0.5 g/L) in reperfusion phase of transplantation 
due to hyperfibrinolysis, while postoperative FBG values 
remained within the limits (Table 2 and Graph 5).
ECLT was presented intraoperatively, since the function 
of the fibrinolytic system was normalised postoperatively 
by antifibrinolytic therapy. Intraoperatively, hyperfibrinol-
ysis dominated in the anhepatic phase of transplantation 
(29±12.0 min) due to increased t-PA levels, but it was also 
present in both preanhepatic (59±42.3 min) and reper-
fusion phases (55±33.1 min) (Table 2 and Graph 6).
D-dimer values were significantly increased in the ma-
jority of patients at the very beginning of transplantation 
(1229±1206.6 ng/mL), which was consistent with the pres-
ence of extravascular fibrinolysis. Intraoperative increase 
of values in reperfusion phase (1393±1220.4 ng/mL) was 
consistent with the accelerated fibrinolysis, while postop-
erative successive increase was due to coagulation system 
activation, showing significantly higher D-dimer values 
(2606±1055.1 ng/mL) on postoperative day 14 (Table 2 
and Graph 7).
In the majority of patients the level of AT activity 
was lower (61±18.0%) at the beginning of transplanta-
tion than it was during transplantation in the anhepatic 
phase (71±16.0%), with normalisation after the surgery 
(82±10.0%), which was constantly maintained at physi-
ological level with an adequate substitution by AT concen-
trate (Table 2 and Graph 8).
Postoperatively, laboratory effects of the parenteral anti-
coagulant therapy were monitored by determination of the 
anti-Xa activity, the level of which was within prophylactic 
range (0.26±0 IU/mL) (Table 2 and Graph 9).
DISCUSSION
The course of orthotopic liver transplantation is charac-
terized by severe impairment of the haemostatic system. 
Preanheptic, explantation phase involves removal of recipi-
ent’s liver and reflects the preoperative state of the damaged 
liver [16]. Bleeding in this phase is mainly surgical and 
can be significant, due to portal hypertension, parenchyma 
vulnerability and possible existence of adhesions from pre-
vious surgical interventions [17]. Anhepatic phase involves 
clamping of large liver blood vessels, portal vein and the 
inferior vena cava. It is characterised by the absence of the 
liver and hepatic clearance [18]. This stage is dominated by 
the fibrinolytic system’s disorder, caused by the increased 
level of t-PA, which is released from the endothelium of 
large blood vessels, while it cannot be eliminated through 
liver due to absence of hepatic clearance or inactivated by 
PAI-1 [18, 19, 20]. Bleeding is nonsurgical, since the large 
blood vessels are clamped, so it is a direct consequence of 
haemostatic disorder due to hyperfibrinolysis [15], the use 
of heparin if applicable during the surgical techniques or 
negative effect of hypothermia, while the appearance of 
dilutional coagulopathy is also possible [21]. Deteriora-
tion of the fibrinolytic system function depends on the 
duration of anhepatic phase – the longer the anhepatic 
phase, the more pronounced hyperfibrinolysis is [22]. The 
postanhepatic, reperfusion phase involves reperfusion of 
donor liver after revascularisation by clamp removal, and 
haemostatic disorders depend on the quality of the liver 
transplant. In this phase, bleeding is a result of hyperfi-
brinolysis [15], heparin release from the transplant, liver 
ischemia and hypothermia [21], dilution effect of cold 
preservation solution residue in the liver after rinsing, 
which inhibits platelet aggregability [23], or the dilution 
effect due to massive transfusion [21], as well as throm-
bocytopenia due to platelet sequestration in the transplant 
and platelet dysfunction caused by the loss of platelet gran-
ules [24, 25]. The damaged cells of the liver sinusoids are 
adhered to by platelets, which release mediators that may 
cause intravascular coagulation [26].
Our study results show preoperative presence of com-
plex haemostatic system disorders in the sample group, 
the dominant being fibrinolytic system impairment, el-
evated D-dimer value, prolonged PT and AT deficiency. 
Significant dysfunction of the fibrinolytic system during 
liver transplantation was also observed by other authors 
[14, 27].
During the liver transplantation, in its various phases, 
there are evident changes of laboratory haemostatic pa-
rameters which correspond to data presented in literature 
[22]. The most pronounced haemostatic disorder during 
transplantation was observed in the anhepatic phase, pre-
dominantly hyperfibrinolysis, prolonged TT and drop of 
the PLT count. In reperfusion phase, there are complex 
haemostatic disorders: high fibrinolytic activity, increase of 
D-dimer values, hypofibrinogenemia, prolonged TT, aPTT, 
PT, and decrease of AT activity. Similar results during liver 
transplantation, particularly in the reperfusion phase, were 
presented in other studies, primarily in the values of FBG, 
prolonged aPTT, TT, decrease in the level of AT, and the 
highest values of D-dimer [27].
Further monitoring after liver transplantation from 
postoperative day 1 revealed a gradual normalisation in 
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the values of the monitored laboratory parameters of the 
haemostatic system in the first week, and our results show 
no significant differences in comparison to the research 
of other authors [22]. The first to normalise were aPTT, 
FBG, AT, normal TT value was recorded on postoperative 
day 3, and from postoperative day 7, PT also restored to 
normal. Moderate thrombocytopenia was evident during 
the first week, reaching the physiological platelet count 
on postoperative day 14, which is in accordance with the 
literature data [28, 29]. D-dimer value showed gradual 
increase, remaining in the significantly high range even 
after two weeks.
Substitution therapy during liver transplantation is nec-
essary because of significant intraoperative bleeding due to 
complexity of the surgical procedure itself and co-occurring 
serious haemostatic changes [13, 30, 31]. Substitution is 
highly dependent on clinical bleeding and laboratory find-
ings as well. It includes fresh frozen plasma, cryoprecipitate, 
PLT concentrate, blood derivatives and AT concentrate. A 
continuous antifibrinolytic therapy is also necessary.
After transplantation, the liver function usually im-
proves after postoperative day 3 [32]. During early post-
operative period, there is an increase of the coagulation 
factor levels [33]. Thrombocytopenia persists for several 
days due to hypersplenism, influence of HLA cytotoxic 
antibodies [22] and immunosuppressive therapy. Hyper-
coagulability follows in later postoperative period, with a 
threat of thromboembolic complications due to different 
recovery rates of factors and inhibitors of coagulation, 
namely, faster normalisation of coagulation factors [33]. 
Moreover, immunosuppressive therapy leads to increased 
levels of FBG, FVIII and PAI-1 [34]. Possible complica-
tions include thrombosis of the anastomosed blood vessels, 
hepatic artery or portal vein, with possible development of 
pulmonary thromboembolism. During the first five days, 
the liver rejection often happens as a consequence of the 
hepatic artery thrombosis [35]. Extensive studies involv-
ing sample groups of 700-1200 transplanted patients state 
that thrombosis develops in the hepatic artery in 2.0-2.7% 
of cases and that it can cause liver graft dysfunction [36, 
37, 38]; therefore, thromboprophylaxis with unfraction-
ated or low-molecular-weight heparin is recommended in 
postoperative period. In our cohort, thromboprophylaxis 
was implemented from the postoperative day 1 with the 
unfractionated heparin in the first 48 hours, followed by 
low molecular weight heparin. The dose was adjusted ac-
cording to the findings of the anti-Xa activity and the levels 
maintained within the prophylactic range.
A continuous monitoring of the haemostatic system 
laboratory parameters is mandatory during the liver trans-
plantation in order to optimise substitution and antifibri-
nolytic therapy during and after transplantation, as well as 
to apply adequate measures to prevent thromboembolic 
complications, depending on patient’s clinical status and 
the estimated risk of haemorrhagic and thromboembolic 
complications.
CONCLUSION
Laboratory monitoring of the haemostatic system changes 
in liver transplantations in our study has shown gradual 
improvement of all investigated laboratory parameters of 
the haemostatic system after the first day after transplanta-
tion, with normalisation within 7-14 days.
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КРАТАК САДРЖАЈ
Увод Код обо  ље  ња је  тре све ком  по  нен  те хе  мо  ста  зног си  сте-
ма су из  ме  ње  не, а по  ре  ме  ћај функ  ци  о  нал  но  сти овог си  сте-
ма сра  зме  ран је хе  па  то  це  лу  лар  ном оште  ће  њу. То  ком тран-
сплан  та  ци  је је  тре вред  но  сти па  ра  ме  та  ра хе  мо  ста  зе зна  чај  но 
се ме  ња  ју, да би се по  сто  пе  ра  ци  о  но за  бе  ле  жи  ла по  сте  пе  на 
нор  ма  ли  за  ци  ја функ  ци  о  нал  но  сти хе  мо  ста  зног си  сте  ма.
Циљ ра  да Циљ ис  тра  жи  ва  ња били су по  сма  тра  ње и бе-
ле  же  ње про  ме  на хе  мо  ста  зног си  сте  ма то  ком и по  сле опе-
ра  ци  је, те утвр  ђи  ва  ње ди  на  ми  ке по  сти  за  ња фи  зи  о  ло  шких 
вред  но  сти па  ра  ме  та  ра на  кон тран  сплан  та  ци  је је  тре.
Ме  то  де ра  да Од ју  на 2008. до фе  бру  а  ра 2012. го  ди  не у 
Кли  нич  ком цен  тру Вој  во  ди  не ура  ђе  но је 17 ка  да  ве  рич  них 
тран  сплан  та  ци  ја је  тре. Ис  пи  ти  ва  ни су сле  де  ћи па  ра  ме  три: 
тром  бо  ци  ти, ак  ти  ви  са  но пар  ци  јал  но тром  бо  пла  стин  ско 
вре  ме, про  тром  бин  ско и тром  бин  ско вре  ме, фи  бри  но  ген, 
еугло  бу  лин  ско вре  ме ли  зе ко  а  гу  лу  ма, D-ди  мер, ан  ти  тром-
бин и хе  па  ри  не  ми  ја. Ре  зул  та  ти су бе  ле  же  ни ин  тра  о  пе  ра  ци-
о  но, по фа  за  ма тран  сплан  та  ци  је, и од пр  вог до сед  мог да  на 
по  сле опе  ра  ци  је, а по  том 14. да  на.
Ре  зул  та  ти Нај  и  зра  же  ни  ји по  ре  ме  ћа  ји уоче  ни то  ком тран-
сплан  та  ци  је је  тре би  ли су: тром  бо  ци  то  пе  ни  ја (96±66,1×109/l), 
про  ду  же  но ак  ти  ви  са  но пар  ци  јал  но тром  бо  пла  стин  ско 
(1,80±0,8 R), про  тром  бин  ско (1,59±0,4 R) и тром  бин  ско вре-
ме (2,03±1,7 R), хи  по  фи  бри  но  ге  не  ми  ја (2,13±0,5 g/l), хи  пер-
фи  бри  но  ли  за (29±12,0 мин.), по  раст D-ди  ме  ра (1393±1220,4 
ng/ml) и пад ан  ти  тром  би  на (61±18,0%). Да  љим пра  ће  њем 
на  кон тран  сплан  та  ци  је, од пр  вог по  сто  пе  ра  ци  о  ног да  на, бе-
ле  жи се по  сте  пе  на нор  ма  ли  за  ци  ја вред  но  сти па  ра  ме  та  ра, 
а фи  зи  о  ло  шке вред  но  сти свих па  ра  ме  та  ра по  стиг  ну  те су 
14. да  на, сем одр  жа  ва  ња по  ви  ше  них вред  но  сти D-ди  ме  ра 
(2606±1055,1 ng/ml). Ни  во хе  па  ри  не  ми  је био је у пре  вен  тив-
ном оп  се  гу (0,26±0 IU/ml).
За  кљу  чак Кон  ти  ну  и  ра  но испитивање па  ра  ме  та  ра хе  мо-
ста  зног си  сте  ма код тран  сплан  та  ци  је је  тре од из  у  зет  ног је 
зна  ча  ја јер омо  гу  ћа  ва оп  ти  мал  ну при  ме  ну суп  сти  ту  ци  о  не 
те  ра  пи  је то  ком и на  кон опе  ра  ци  је и од  го  ва  ра  ју  ће по  сто-
пе  ра  ци  о  не тром  бо  про  фи  лак  се. Резултати лабораторијског 
испитивања указују на нормализовање вредности хемо- 
стазних параметара током 7–14 дана након трансплантације 
јетре.
Кључ  не ре  чи: хе  мо  ста  за; хе  мо  ста  зни па  ра  ме  три; фи  бри  но-
ли  за; ор  то  то  пич  на тран  сплан  та  ци  ја је  тре
Лабораторијско испитивање промена хемостазног система током 
ортотопичне трансплантације јетре
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